Aqilion strengthens its operational team in line with the company’s research strategy
Aqilion announced today that Johan Lund, the current Chairman of the company, will join the operational team as Chief Scientific Officer beginning on March 1. Johan Lund will mainly contribute his expertise in the field of inflammation research, which is Aqilion’s research priority. During its journey of change, Aqilion has transitioned from being a company that invested in startup companies to launching wholly owned projects with potential to break new ground in the development of innovative therapies. The company is focusing on novel therapies for patients with diseases primarily in